Rechercher
image du produit
Lancet Oncology, The

S'abonner

Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study - 28/09/13

Doi : 10.1016/S1470-2045(13)70366-8 
Dean Ornish, ProfMD a, h, ⁎ , Jue Lin, PhD b, June M Chan, ProfPhD e, f, Elissa Epel, PhD c, Colleen Kemp, RN h, Gerdi Weidner, ProfPhD g, Ruth Marlin, MD h, Steven J Frenda, MA h, Mark Jesus M Magbanua, PhD e, Jennifer Daubenmier, PhD a, Ivette Estay, PhD h, Nancy K Hills, PhD f, Nita Chainani-Wu, DMD d, Peter R Carroll, ProfMD e, Elizabeth H Blackburn, ProfPhD b
a Department of Medicine, University of California San Francisco, San Francisco, CA, USA 
b Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA 
c Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA 
d Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA, USA 
e Department of Urology, Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California San Francisco, San Francisco, CA, USA 
f Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA 
g Department of Biology, San Francisco State University, San Francisco, CA, USA 
h Preventive Medicine Research Institute, Sausalito, CA, USA 

* Correspondence to: Prof Dean Ornish, Preventive Medicine Research Institute, 900 Bridgeway, Suite 1, Sausalito, CA 94965, USA

Summary

Background

Telomere shortness in human beings is a prognostic marker of ageing, disease, and premature morbidity. We previously found an association between 3 months of comprehensive lifestyle changes and increased telomerase activity in human immune-system cells. We followed up participants to investigate long-term effects.

Methods

This follow-up study compared ten men and 25 external controls who had biopsy-proven low-risk prostate cancer and had chosen to undergo active surveillance. Eligible participants were enrolled between 2003 and 2007 from previous studies and selected according to the same criteria. Men in the intervention group followed a programme of comprehensive lifestyle changes (diet, activity, stress management, and social support), and the men in the control group underwent active surveillance alone. We took blood samples at 5 years and compared relative telomere length and telomerase enzymatic activity per viable cell with those at baseline, and assessed their relation to the degree of lifestyle changes.

Findings

Relative telomere length increased from baseline by a median of 0·06 telomere to single-copy gene ratio (T/S)units (IQR–0·05 to 0·11) in the lifestyle intervention group, but decreased in the control group (−0·03 T/S units, −0·05 to 0·03, difference p=0·03). When data from the two groups were combined, adherence to lifestyle changes was significantly associated with relative telomere length after adjustment for age and the length of follow-up (for each percentage point increase in lifestyle adherence score, T/S units increased by 0·07, 95% CI 0·02–0·12, p=0·005). At 5 years, telomerase activity had decreased from baseline by 0·25 (–2·25 to 2·23) units in the lifestyle intervention group, and by 1·08 (–3·25 to 1·86) units in the control group (p=0·64), and was not associated with adherence to lifestyle changes (relative risk 0·93, 95% CI 0·72–1·20, p=0·57).

Interpretation

Our comprehensive lifestyle intervention was associated with increases in relative telomere length after 5 years of follow-up, compared with controls, in this small pilot study. Larger randomised controlled trials are warranted to confirm this finding.

Funding

US Department of Defense, NIH/NCI, Furlotti Family Foundation, Bahna Foundation, DeJoria Foundation, Walton Family Foundation, Resnick Foundation, Greenbaum Foundation, Natwin Foundation, Safeway Foundation, Prostate Cancer Foundation.

Le texte complet de cet article est disponible en PDF.

Plan


© 2013  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 14 - N° 11

P. 1112-1120 - octobre 2013 Retour au numéro
Article précédent Article précédent
  • Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
  • Luana Calabrò, Aldo Morra, Ester Fonsatti, Ornella Cutaia, Giovanni Amato, Diana Giannarelli, Anna Maria Di Giacomo, Riccardo Danielli, Maresa Altomonte, Luciano Mutti, Michele Maio
| Article suivant Article suivant
  • Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
  • Stephen E Jones, Rufus Collea, Devchand Paul, Scot Sedlacek, Anne M Favret, Ira Gore, Deborah L Lindquist, Frankie Ann Holmes, Mary Ann K Allison, Barry D Brooks, Raul M Portillo, Svetislava J Vukelja, Michael S Steinberg, Christopher Stokoe, Maria W Crockett, Yunfei Wang, Lina Asmar, Nicholas J Robert, Joyce O’Shaughnessy

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.